The positive impact of adjuvants on vaccination can be functional and practical. A handful of adjuvants are currently licensed for human vaccination, and a number of new adjuvants have reached advanced development stages. However, access to these and other adjuvants is limited. Presented at the 2012 Conference on Modern Vaccines Adjuvants and Delivery Systems, this poster outlines PATH’s work to expand access to proprietary and non-proprietary adjuvants as well as relevant formulations technologies to facilitate their successful exploration and use by product development partnerships and developing-country vaccine manufacturers.
Author(s): Blum J, Chen D, Cummings R
Corporate author(s): PATH
Publication date: June 2012
564 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA